MAPT and supranuclear palsy, progressive, 1: In conclusion, our findings show that [18F]PI-2620 PET data scaled with temporo-orbital WM is superior to conventional reference region methods for quantification of tau in 4R tauopathies and could be used in clinical trials to track disease progression or aid in molecularly defined diagnosis of PSP.